First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

10.1177/1758835919836374

Saved in:

Bibliographic Details
Main Authors:	Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Review
Language:	English
Published:	SAGE PUBLICATIONS LTD 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218616
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-218616
record_format	dspace
spelling	sg-nus-scholar.10635-2186162023-10-31T20:32:39Z First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin DUKE-NUS MEDICAL SCHOOL Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY 10.1177/1758835919836374 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 11 2022-04-07T08:32:48Z 2022-04-07T08:32:48Z 2019-04-01 2022-04-07T02:39:05Z Review Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin (2019-04-01). First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 11. ScholarBank@NUS Repository. https://doi.org/10.1177/1758835919836374 17588340 17588359 https://scholarbank.nus.edu.sg/handle/10635/218616 en SAGE PUBLICATIONS LTD Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
description	10.1177/1758835919836374
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin
format	Review
author	Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin
author_sort	Park, Keunchil
title	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
title_short	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
title_full	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
title_fullStr	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
title_full_unstemmed	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
title_sort	first-line afatinib for the treatment of egfr mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
publisher	SAGE PUBLICATIONS LTD
publishDate	2022
url	https://scholarbank.nus.edu.sg/handle/10635/218616
_version_	1781793042274975744

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

Similar Items